Moore N, Lecointre D, Noblet C, Mabille M
Department of Pharmacology, Université V. SEGALEN, CHU de Bordeaux, France.
Br J Clin Pharmacol. 1998 Mar;45(3):301-8. doi: 10.1046/j.1365-2125.1998.00667.x.
To assess the frequency and cost of drug reactions causing or prolonging hospitalization.
All patients admitted to an internal medicine ward over 6 months were evaluated to identify serious adverse reactions. The number of drug classes on admission or at the time of the adverse drug reaction (ADR) was counted. Excess ADR-related hospital stay was computed using a) raw excess duration of hospital stay, b) correction of duration of hospital stay by age, sex, and number of drug classes, and c) estimation by investigator of excess hospital stay.
Three hundred and twenty-nine patients were evaluated: 212 male, 117 female, mean age 57.2 (males: 52.2, females: 66.2 (P < 0.05)), range 17-95 years. They stayed a total of 3720 hospital days (mean stay 11.3 days). 298 had no ADR (mean age 55.8, taking a mean of 2.7 drug classes, 10.7 days hospital stay); 31 had ADRs: in 10, the ADR caused admission in patients with a mean age of 84 (P < 0.01 vs the two other groups), taking 6.3 drug classes, who stayed a mean of 15.1 days; 21 occurred in hospital in patients with a mean age of 63.6, taking 4.2 drug classes (P < 0.01), who stayed a mean of 19.2 days (P < 0.01 vs patients without ADRs). In four the ADR was fatal (13% of ADRs, 40% of deaths). Raw ADR-related excess hospital stay was 318 days (8.6% of all hospital days), after multivariate correction 282 days (7.6% of all hospital days), and with investigator estimation 197 days (5.3% of all hospital days). Point prevalence of ADRs at admission was 3%, incidence rate in hospital was 5.6/1000 patient-days.
3% of the admissions were related to ADRs. In addition, 6.6% of hospitalized patients had significant ADRs. Between 5 and 9% of hospital costs were related to ADRs. In 24 of the 31 patients with ADRs (77%), these were related to the pharmacological properties of the involved drugs, and may possibly have been avoidable.
评估导致或延长住院时间的药物不良反应的发生率及成本。
对内科病房6个月内收治的所有患者进行评估,以确定严重不良反应。统计入院时或发生药物不良反应(ADR)时的药物种类数量。使用以下方法计算与ADR相关的额外住院时间:a)住院时间的原始额外时长;b)根据年龄、性别和药物种类数量对住院时间进行校正;c)由研究者估算额外住院时间。
共评估了329例患者:男性212例,女性117例,平均年龄57.2岁(男性:52.2岁,女性:66.2岁(P<0.05)),年龄范围为17 - 95岁。他们总共住院3720天(平均住院11.3天)。298例无ADR(平均年龄55.8岁,平均使用2.7种药物,住院10.7天);31例发生ADR:其中10例ADR导致患者入院,平均年龄84岁(与其他两组相比P<0.01),使用6.3种药物,平均住院15.1天;21例在住院期间发生,平均年龄63.6岁,使用4.2种药物(P<0.01),平均住院19.2天(与无ADR患者相比P<0.01)。4例ADR导致死亡(占ADR的13%,占死亡病例的40%)。与ADR相关的原始额外住院时间为318天(占总住院天数的8.6%),多因素校正后为282天(占总住院天数的7.6%),研究者估算为197天(占总住院天数的5.3%)。入院时ADR 的时点患病率为3%,住院期间的发病率为5.6/1000患者日。
3%的入院病例与ADR有关。此外,6.6%的住院患者发生了严重ADR。5%至9%的住院费用与ADR有关。在31例发生ADR的患者中,有24例(77%)与所涉药物的药理特性有关,可能是可以避免的。